INCR Intercure Ltd. IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1857030 · Reporting currency ILS · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: ILS | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 | FY20202020-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 238.84M | 355.55M | 388.68M | 219.68M | 65.03M |
| Cost of revenue | 203.25M | 247.21M | 229.73M | 123.69M | 34.65M |
| Gross profit | 30.23M | 105.09M | 155.08M | 91.13M | 31.98M |
| R&D expense | 414,000 | 388,000 | 632,000 | 1.24M | 1.58M |
| SG&A expense | 53.67M | 42.61M | 36.08M | 27.21M | 8.59M |
| Operating income | -67.21M | -41.57M | 50.63M | 28.18M | -38.40M |
| Pretax income | -87.32M | -61.28M | 43.84M | 18.73M | -38.31M |
| Income tax | -14.53M | 2.25M | 93,000 | 11.44M | -2.27M |
| Net income | -67.80M | -61.96M | 44.82M | 4.69M | -37.23M |
| EBITDA | -51.84M | -28.40M | 62.33M | 35.58M | -35.15M |
| EPS (basic) | -1.48 | -1.36 | 0.99 | 0.12 | -1.42 |
| EPS (diluted) | -1.48 | -1.36 | 0.99 | 0.11 | -1.42 |
| Balance sheet | |||||
| Cash & equivalents | 78.32M | 101.14M | 232.59M | 196.22M | 37.89M |
| Short-term investments | 333,000 | 187,000 | 157,000 | 330,000 | — |
| Receivables | 51.85M | 60.41M | 36.92M | 17.41M | 12.47M |
| Inventory | 120.31M | 105.47M | 140.13M | 62.31M | 19.05M |
| Current assets | 391.80M | 418.80M | 527.49M | 336.16M | 76.65M |
| PP&E, netmay include right-of-use assets (IFRS) | 105.24M | 97.47M | 103.13M | 86.51M | 53.47M |
| Goodwill | 224.59M | 221.08M | 284.18M | 268.29M | 190.10M |
| Total assets | 762.57M | 786.61M | 958.01M | 696.54M | 326.27M |
| Current liabilities | 226.75M | 225.87M | 312.72M | 193.59M | 29.88M |
| Short-term debt | 69.44M | 88.19M | 126.94M | 70.56M | 357,000 |
| Long-term debt | 113.98M | 82.20M | 99.68M | 11.88M | 388,000 |
| Total debt | 183.41M | 170.40M | 226.62M | 82.44M | 745,000 |
| Total liabilities | 364.90M | 329.55M | 436.53M | 227.13M | 34.16M |
| Shareholders' equity | 396.97M | 455.11M | 501.31M | 448.03M | 274.51M |
| Net debt | 105.10M | 69.26M | -5.97M | -113.78M | -37.14M |
| Cash flow statement | |||||
| Operating cash flow | -66.93M | -53.63M | 51.27M | 30.14M | 7.90M |
| Capital expenditure | 4.38M | 2.62M | 19.74M | 14.03M | 20.84M |
| Free cash flow | -71.30M | -56.25M | 31.52M | 16.11M | -12.95M |
| Investing cash flow | 17.69M | 4.77M | -142.50M | -65.21M | -22.76M |
| Financing cash flow | 26.45M | -82.89M | 120.45M | 197.94M | 25.20M |
| Depreciation & amortization | 15.37M | 13.17M | 11.70M | 7.39M | 3.25M |
| Stock-based compensation | 2.28M | 2.59M | 8.91M | 6.45M | 10.01M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· Amounts are in the company's reporting currency, ILS, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.